Published in World J Diabetes on August 10, 2015
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (REWIND) | NCT01394952
Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol (2016) 0.79
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. Ther Clin Risk Manag (2017) 0.75
Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes. Cardiovasc Diabetol (2016) 0.75
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2015) 12.05
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care (2004) 4.17
Incorporating lag time to benefit into prevention decisions for older adults. JAMA (2013) 2.40
HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (2013) 2.21
Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care (2007) 2.13
Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes (2009) 1.83
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res (2015) 1.73
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol (2011) 1.34
Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J (1991) 1.17
Arterial stiffness in diabetes mellitus. Atherosclerosis (2014) 1.09
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diab Vasc Dis Res (2015) 1.06
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J (2015) 0.88
Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects. Scand J Clin Lab Invest (2007) 0.85
Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis. Scand J Clin Lab Invest (2007) 0.84
Contributors to mortality in high-risk diabetic patients in the Diabetes Heart Study. Diabetes Care (2014) 0.84
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag (2007) 0.83
Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls. J Diabetes (2015) 0.79